Stomatitis
Drug research and approvals for stomatitis: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 51 studies of stomatitis are recruiting on ClinicalTrials.gov, Health Canada has authorized 0 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 51
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Oral Care Program for Mouth Side Effects During Head and Neck Radiation TherapyNCT07885033 · Not applicable · UNCANCER LLC · starts Nov 1, 2026
- Study of a Copaiba-Based Mouthwash Combined With Low-Level Laser Therapy in the Prevention of Oral Mucositis in…NCT07810530 · Phase 2 · Instituto Nacional de Cancer, Brazil · starts Mar 29, 2026
- Protective Role of Alpha-Lipoic Acid in Chemotherapy-Induced MucositisNCT07736495 · Phase 2 / Phase 3 · Ain Shams University · starts Jul 27, 2026
- The Preventive and Therapeutic Effects of Spirulina Preparations on Ulcers of Oral MucosaNCT07723612 · Not applicable · The Fourth Affiliated Hospital of Zhejiang University School of Medicine · starts Jun 1, 2026
- Chlorophyllin for Reducing Oral Mucositis in Total Body Irradiation Prior to TransplantNCT07709195 · Phase 2 · Tata Memorial Centre · starts Oct 30, 2024
- A Clinical Study to Compare BupiZenge With Lidocaine for Pain Due to Oral Mucositis in Patients With Head and Neck…NCT07672236 · Phase 3 · OncoZenge AB · starts Jul 7, 2026
- Observational Study of OROSEDAL in Sore Throat and Minor Oral LesionsNCT07620353 · Not reported · Laboratoires Elerte · starts Mar 5, 2026
- Taurine for the Prevention and Treatment of Radiation-induced Oral Mucositis in Patients With Nasopharyngeal CarcinomaNCT07567742 · Phase 2 · Sun Yat-sen University · starts May 8, 2026
- MucoLock™ for Treatment of StomatitisNCT07506018 · Not applicable · Baptist Health South Florida · starts Jul 16, 2026
Approved 1
- PaliferminFibroblast growth factor receptor 2 agonist
Phase 3 12 of 16
- CisplatinDNA inhibitor
- DoxepinNorepinephrine transporter inhibitor
- BenzydamineCyclooxygenase inhibitor
- Avasopasem manganeseAntioxidant, superoxide dismutase mimetic
- Curcumin
- ThalidomideCRL4(CRBN) E3 ubiquitin ligase inhibitor
- LidocaineSodium channel alpha subunit blocker
- DiphenhydramineHistamine H1 receptor antagonist
- NystatinErgosterol sequestering agent
- Glutamine
- Bifidobacterium spp.Probiotic
- Lactobacillus acidophilusProbiotic
Phase 2 12 of 25
- CelecoxibCyclooxygenase-2 inhibitor
- ClonidineAdrenergic receptor alpha-2 agonist
- EtanerceptTNF-alpha inhibitor
- MorphineMu opioid receptor agonist
- ChlorhexidineCell membrane inhibitor
- AmlexanoxPhosphodiesterase 4 inhibitor
- MiconazoleCytochrome P450 51 inhibitor
- Meclocycline sulfosalicylateBacterial 70S ribosome inhibitor
- Omega-3-ACID ethyl esters
- Aluminum hydroxideAntacid
- CobiprostoneChloride channel protein 2 activator
- ClazakizumabInterleukin-6 inhibitor
Phase 1 or earlier 3
- HeparinAntithrombin-III activator
- PhenylephrineAdrenergic receptor alpha-1 agonist
- MelatoninMelatonin receptor agonist
How its trials ended
354 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 58 whose ending is known, 33% met their primary endpoint, 7% missed it and 60% stopped early.
- Completed, result not reported16747%
- Ongoing6619%
- Status unknown6318%
- Met its primary endpoint195%
- Stopped: other or unclear165%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint41%
- Stopped: sponsor or business decision41%
- Stopped: lack of efficacy31%
- Stopped: funding31%
- Stopped: safety1<1%
| Jun 29, 1999 | Lactic acidTreatment of severe aphthous stomatitis in severely, terminally immunocompromised patients. | Frontier Pharmaceutical, Inc. | Designated |
| May 1, 1995 | ThalidomideTreatment of severe recurrent aphthous stomatitis in severely, terminally immunocompromised patients. | Celgene Corporation | Designated |
| Jul 15, 1993 | SucralfateTreatment of oral mucositis and stomatitis following radiation therapy for head and neck cancer. | Fuisz Technologies, Ltd. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA